Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume
European Urology Focus · 2023-09 · 9 (5) · 838-842
DOI: 10.1016/j.euf.2023.03.024 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift European Urology Focus, 2023-09. Verfasst von Benedikt Hoeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Two randomized controlled trials recently demonstrated an overall survival benefit with triplet therapy (androgen receptor axis-targeted agent [ARAT] + docetaxel + androgen deprivation therapy [ADT]) over doublet therapy (docetaxel + ADT) in metastatic hormone-sensitive prostate cancer (mHSPC), broadening the treatment options. In our previous systematic review and network meta-analysis on the role of triplet versus doublet therapy, we focused on ARAT + ADT, as this is the actual standard of care in many countries for mHSPC. However, survival data by disease volume were only available for one triplet therapy regimen (PEACE-1). Survival data stratified by disease volume for a second triplet regimen (ARASENS) are now available, hence we updated our meta-analysis for low- and high-volume mHSPC. Consistent with previous findings, ADT alone no longer represents a valid treatment option for mHSPC. Similar considerations apply to doublet therapy with docetaxel + ADT. For low-volume mHSPC, in comparison to ADT, the benefit of combination therapies other than ARAT + ADT was not substantial. For high-volume mHSPC, darolutamide + docetaxel + ADT ranked first (P score 0.92), followed by abiraterone + docetaxel + ADT (P score 0.85) and then ARAT + ADT combination therapies. In high-volume mHSPC, only darolutamide + docetaxel + ADT demonstrated superior overall survival (hazard ratio 0.76, 95% confidence interval 0.59-0.97) versus (pooled) ARAT + ADT, confirming the importance of triplet therapy in (high-volume) mHSPC. PATIENT SUMMARY: We performed an updated comparison of double and triple therapy options for metastatic prostate cancer that still responds to hormone treatment. For patients with low-volume cancer, there was no significant survival benefit from addition of a third drug. For patients with high-volume cancer, the best survival was obtained with darolutamide + docetaxel + androgen deprivation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Cent…
- Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Canada.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospi…
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. Electronic address: philipp.mandel@kgu.de.
Zitieren
APA
Hoeh, B., Garcia, C. C., Wenzel, M., Tian, Z., Tilki, D., Steuber, T., Karakiewicz, P. I., Chun, F. K. H., & Mandel, P. (2023). Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. European Urology Focus, 9(5), 838-842. https://doi.org/10.1016/j.euf.2023.03.024
Vancouver
Hoeh B, Garcia CC, Wenzel M, Tian Z, Tilki D, Steuber T, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. European Urology Focus. 2023;9(5):838-842. doi:10.1016/j.euf.2023.03.024
BibTeX
@article{Hoeh2023,
author = {Hoeh, Benedikt and Garcia, Cristina Cano and Wenzel, Mike and Tian, Zhe and Tilki, Derya and Steuber, Thomas and Karakiewicz, Pierre I and Chun, Felix K H and Mandel, Philipp},
title = {Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume},
journal = {European Urology Focus},
year = {2023},
volume = {9},
number = {5},
pages = {838--842},
doi = {10.1016/j.euf.2023.03.024}
}
EUVIMED